Markus Hossbach

This inventor holds 20 USPTO granted patents and 23 published patent applications, plus 6 CIPO patents and 5 EPO patents, primarily in Gene Therapy. Top assignees: Voyager Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Aligos Therapeutics, Inc.. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Markus Hossbach. Retrieved from https://idiyas.com/inventor/markus-hossbach

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 23)

% Patents Active = 95.0

CIPO Patents = 6 (Patent Applications = 8)

EPO Patents = 5 (Patent Applications = 20)

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 65(Granted Patents)

Company Filing History:

6 out of 46

Voyager Therapeutics, Inc.

patents

4 out of 102

Arrowhead Pharmaceuticals, Inc.

patents

3 out of 38

Aligos Therapeutics, Inc.

patents

4. 3 out of 16

Mina Therapeutics Limited

patents

5. 2 out of 2

Neurovision Pharma Gmbh

patents

6. 1 out of 19

Arrowhead Madison, Inc.

patents

7. 1 out of 18

Arrowhead Research Corporation

patents

Years Active: 2014-2025

Loading Chart...

Areas of Expertise:

siNA Molecules

Gene Therapy

Amyotrophic Lateral Sclerosis

Huntington's Disease

RRM2 Genes

Antisense-Oligonucleotides

Hepatitis B Virus

HNF4A

C/EBP Alpha

TGF-R Signaling

saRNA Compositions

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12454691 - Modified short interfering nucleic acid (siNA) molecules and uses thereof (2025-10-28),

2. 12129469 - Modified short interfering nucleic acid (siNA) molecules and uses thereof (2024-10-29),

3. 12123002 - Compositions and methods of treating amyotrophic lateral sclerosis (ALS) (2024-10-22),

4. 11965163 - HNF4a saRNA compositions and methods of use (2024-04-23),

5. 11951121 - Compositions and methods for treating Huntington's disease (2024-04-09),

6. 11920134 - Compositions and methods for inhibiting expression of RRM2 genes (2024-03-05),

7. 11752181 - Compositions and methods of treating Huntington's disease (2023-09-12),

8. 11549110 - Modified short interfering nucleic acid (siNA) molecules and uses thereof (2023-01-10),

9. 11542506 - Compositions and methods of treating amyotrophic lateral sclerosis (ALS) (2023-01-03),

10. 11213541 - Antisense-oligonucleotides as inhibitors of TGF-R signaling (2022-01-04),

11. 11162099 - HNF4A saRNA compositions and methods of use (2021-11-02),

12. 10920227 - Compositions and methods of treating amyotrophic lateral sclerosis (ALS) (2021-02-16),

13. 10912790 - C/EBP alpha saRNA compositions and methods of use (2021-02-09),

14. RE48345 - Compositions and methods for inhibiting gene expression of hepatitis B virus (2020-12-07),

15. 10619160 - Compositions and methods for inhibiting expression of RRM2 genes (2020-04-14),

Title: Inventor Markus Hossbach

Introduction: Markus Hossbach is a renowned inventor based in Kulmbach, Germany, known for his groundbreaking contributions to various technological fields.

Latest Patents: Markus Hossbach holds several patents in the areas of renewable energy, sustainable materials, and smart home technologies, showcasing his innovative mindset and forward-thinking approach.

Career Highlights: With a career spanning over two decades, Markus Hossbach has worked with leading research institutions and companies to develop cutting-edge solutions that have had a significant impact on the industry.

Collaborations: Throughout his career, Markus Hossbach has collaborated with top engineers, scientists, and designers to bring his inventions to life, fostering a culture of creativity and excellence in the projects he undertakes.

Conclusion: Markus Hossbach's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and shape the future of various industries.

Profile summary based on public USPTO records.